SCHEDULE: FMR LLC Reports 3.9% Stake in Cytokinetics

FMR LLC, through its subsidiaries and affiliates, has disclosed beneficial ownership of 5,248,579.71 shares, representing 3.9% of the outstanding common stock of Cytokinetics Inc., as of June 30, 2026.

Summary

• FMR LLC, along with its affiliates and subsidiaries, has filed a Schedule 13G, indicating beneficial ownership of Cytokinetics Inc. common stock.
• The filing, dated June 30, 2026, reports a total of 5,248,579.71 shares owned.
• This holding represents 3.9% of the total outstanding class of securities.
• FMR LLC exercises sole voting power over 5,220,899.426 shares and sole dispositive power over 5,248,579.71 shares.
• Abigail P. Johnson, a Director, Chairman, and CEO of FMR LLC, is also listed, with her beneficial ownership aggregated under FMR LLC.
• The filing clarifies that these securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It represents a standard disclosure of beneficial ownership by a large institutional investor and does not inherently signal positive or negative performance for Cytokinetics.

Positives

• FMR LLC, a significant investment management entity, holds a substantial stake in Cytokinetics, suggesting confidence in the company's prospects.
• The filing indicates that the shares were acquired and are held in the ordinary course of business, implying a standard investment strategy rather than a hostile takeover attempt.

Negatives

• The filing does not contain any negative financial results or operational challenges for Cytokinetics.

Risks

• The filing does not explicitly mention any current issues or potential future challenges for Cytokinetics.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from Cytokinetics. It is a disclosure of beneficial ownership by FMR LLC.

Management Comments

• "This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the 'FMR Reporters')."
• "The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares."
• "Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC."
• "This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998)."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors like FMR LLC when their ownership stake in a public company crosses a certain threshold (typically 5%). This filing indicates FMR LLC's continued interest and investment in the biotechnology sector, specifically in companies like Cytokinetics that are involved in developing novel therapeutics.

Stakeholder Impact

• Shareholders: The filing confirms FMR LLC's significant investment, which can be seen as a vote of confidence, potentially influencing market perception. However, it does not directly impact current share value or dividends.
• Management: The disclosure is a routine regulatory requirement and does not directly affect Cytokinetics' management or operations.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• FMR LLC will continue to hold and potentially adjust its beneficial ownership of Cytokinetics' common stock in accordance with its investment strategies.
• Cytokinetics will continue its operations and development activities as outlined in its other public disclosures.

Key Dates

Keywords

Cytokinetics, FMR LLC, Schedule 13G, Beneficial Ownership, Common Stock, Investment, SEC Filing, Securities